进化论与肿瘤生态

doi:10.3760/cma.j.issn.1673422X.2016.12.007

摘要/Abstract

摘要： 随着治疗方式、抗肿瘤药物的快速发展，恶性肿瘤的治疗效果已显著提升。但由于耐药的发生，治疗不可避免地走向失败。肿瘤作为一个动态的生态系统，其在发生、发展过程中宿主微环境及肿瘤细胞本身均表现出进化上的差异，使得肿瘤内在环境以及细胞群体均具有丰富的时间和空间异质性，而异质性则是肿瘤发生耐药的基础。

关键词: 肿瘤, 进化

Abstract: With the rapid development of the potential medicine and the treatment protocols, the treatment effect had been improved significantly. Treatment inevitably fails because of the evolution of the resistant cells. As a dynamic ecosystem, in the occurrence and development process of tumors, the tumor microenvironment and tumor cells themselves show differences in the evolution, which enable tumor microenvironment and tumor cells have abundant heterogeneity in time and spatial that is the foundation for the evolution of the resistant cells.

Key words: Neoplasms, Evolution

翁一鸣, 胡伟国, 宋启斌. 进化论与肿瘤生态[J]. 国际肿瘤学杂志, 2016, 43(12): 911-914.

WENG Yi-Ming, HU Wei-Guo, SONG Qi-Bin. Darwinian evolution and tumor ecosystem[J]. Journal of International Oncology, 2016, 43(12): 911-914.

参考文献

［1］ Gatenby RA, Silva AS, Gillies RJ, et al. Adaptive therapy［J］. Cancer Res, 2009, 69(11): 48944903. DOI: 10.1158/00085472.CAN083658. ［2］Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stemlike states, and drug resistance［J］. Mol Cell, 2014, 54(5): 716727. DOI: 10.1016/j.molcel.2014.05.015. ［3］Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer［J］. Nat Rev Cancer, 2014, 14(5): 371380. DOI: 10.1038/nrc3712. ［4］EnriquezNavas PM, Wojtkowiak JW, Gatenby RA. Application of evolutionary principles to cancer therapy［J］. Cancer Res, 2015, 75(22): 46754680. DOI: 10.1158/00085472.CAN151337. ［5］Kam Y, Das T, Tian H, et al. Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges"［J］. Int J Cancer, 2015, 136(4): E188E196. DOI: 10.1002/ijc.29158. ［6］Silva AS, Kam Y, Khin ZP, et al. Evolutionary approaches to prolong progressionfree survival in breast cancer［J］. Cancer Res, 2012, 72(24): 63626370. DOI: 10.1158/00085472.CAN122235. ［7］Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFRmutant nonsmall cell lung cancer with evolutionary cancer modeling［J］. Sci Transl Med, 2011, 3(90): 90ra59. DOI: 10.1126/scitranslmed.3002356. ［8］Gatenby RA. A change of strategy in the war on cancer［J］. Nature, 2009, 459(7246): 508509. DOI: 10.1038/459508a. ［9］Gay L, Baker AM, Graham TA. Tumour cell heterogeneity［J］. F1000Res, 2016, 5: pii: F1000 Faculty Rev238. DOI: 10.12688/f1000research.7210.1. ［10］ Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing［J］. Science, 2014, 346(626): 256259. DOI: 10.1126/science.1256930. ［11］ Cai W, Lin D, Wu C, et al. Intratumoral heterogeneity of ALKRearranged and ALK/EGFR coaltered lung adenocarcinoma［J］. J Clin Oncol, 2015, 33(32): 37013709. DOI: 10.1200/JCO.2014.58.8293. ［12］ Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F［J］. N Engl J Med, 2016, 374(1): 5461. DOI: 10.1056/NEJMoa1508887. ［13］ Gainor JF, Tan DS, De Pas T, et al. Progressionfree and overall survival in ALKpositive NSCLC patients treated with sequential crizotinib and ceritinib［J］. Clin Cancer Res, 2015, 21(12): 27452752. DOI: 10.1158/10780432.CCR143009. ［14］ Shaw AT, Engelman JA. Crizotinib resensitization by compound mutation［J］. N Engl J Med, 2016, 374(18): 17901791. DOI: 10.1056/NEJMc1601366. ［15］ Allred DC, Brown P, Medina D. The origins of estrogen receptor alphapositive and estrogen receptor alphanegative human breast cancer［J］. Breast Cancer Res, 2004, 6(6): 240245. DOI: 10.1186/bcr938. ［16］ Martins VC, Busch K, Juraeva D, et al. Cell competition is a tumour suppressor mechanism in the thymus［J］. Nature, 2014, 509(751): 465470. DOI: 10.1038/nature13317. ［17］ Moreno E. Is cell competition relevant to cancer?［J］. Nat Rev Cancer, 2008, 8(2): 141147. DOI: 10.1038/nrc2252. ［18］ Wishart GC, Plumb JA, Going JJ, et al. Pglycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies［J］. Br J Cancer, 1990, 62(5): 758761. ［19］Dalton WS, Grogan TM, Meltzer PS, et al. Drugresistance in multiple myeloma and nonHodgkin′s lymphoma: detection of Pglycoprotein and potential circumvention by addition of verapamil to chemotherapy［J］. J Clin Oncol, 1989, 7(4): 415424. ［20］ Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebocontrolled randomized trial［J］. J Clin Oncol, 1994, 12(9): 17711777. ［21］ Tsuruo T, Iida H, Kitatani Y, et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drugresistant tumor cells［J］. Cancer Res, 1984, 44(10): 43034307. ［22］ Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance［J］. Clin Cancer Res, 2008, 14(9): 25192526. DOI: 10.1158/10780432.CCR072223. ［23］ Chiappori AA, Soliman H, Janssen WE, et al. INGN225: a dendritic cellbased p53 vaccine (Ad.p53DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect［J］. Expert Opin Biol Ther, 2010, 10(6): 983991. DOI: 10.1517/14712598.2010.484801. ［24］ Dovedi SJ, Adlard AL, LipowskaBhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PDL1 blockade［J］. Cancer Res, 2014, 74(19): 54585468. DOI: 10.1158/00085472.CAN141258. ［25］ Dal Bello MG, Alama A, Barletta G, et al. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors［J］. Int J Cancer, 2015, 137(12): 29472958. DOI: 10.1002/ijc.29647. ［26］ Bissell MJ, Hines WC. Why don′t we get more cancer? A proposed role of the microenvironment in restraining cancer progression［J］. Nat Med, 2011, 17(3): 320329. DOI: 10.1038/nm.2328. ［27］ Langley RR, Fidler IJ. The seed and soil hypothesis revisitedthe role of tumorstroma interactions in metastasis to different organs［J］. Int J Cancer, 2011, 128(11): 25272535. DOI: 10.1002/ijc.26031. ［28］ Oezdemir BC, PentchevaHoang T, Carstens JL, et al. Depletion of CarcinomaAssociated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival［J］. Cancer Cell, 2014, 25(6): 719734. DOI: 10.1016/j.ccr.2014.04.005. ［29］ Kalluri R, Zeisberg M. Fibroblasts in cancer［J］. Nat Rev Cancer, 2006, 6(5): 392401. ［30］ Gillies RJ, Gatenby RA. Metabolism and its sequelae in cancer evolution and therapy［J］. Cancer J, 2015, 21(2): 8896. DOI: 10.1097/PPO.0000000000000102.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.